OVERVIEW

2nd Annual Live Medical Crossfire: Hematologic Malignancies Online is organized by Physicians' Education Resource, LLC (PER).

Release Date: September 28, 2018
Expiration Date: September 28, 2019

The target audience for this medical event is directed toward hematologists and medical oncologists. Nurse practitioners, nurses, physician assistants, pharmacists, investigators, and other health care professionals interested in the treatment of cancer will be invited to participate. This CME Conference has been approved for a maximum of 8.0 Credits.

Description:
The 2nd Annual Live Medical Crossfire: Hematologic Malignancies was a live, full-day version of the renowned Medical Crossfire® format. This 1-day conference was developed to allow you to explore many of the most hotly debated clinical issues in the management of hematologic malignancies. Furthermore, this meeting was designed to facilitate the practical application of emerging data key to treating a broad range of hematologic malignancies, providing you with the information you need to confidently make personalized clinical decisions for your patients and apply novel strategies to real-world clinical case scenarios you routinely encounter in your practice.

For the Live Medical Crossfire®, we assembled renowned experts in the management of leukemias, lymphomas, and myeloma to facilitate discussion both among the faculty and with you in the audience. The program format for this meeting was unique. Each tumor’s section began with a brief evidence-based assessment of the evolving therapeutic space and transitioned quickly to the accompanying clinical questions that were the focus of the expert crossfire session. Each section concluded with a crossfire from the live audience at the meeting.

This online activity captures all the lectures presented at the 2018 2nd Annual Live Medical Crossfire: Hematologic Malignancies and organizes them in a convenient modular format.

Learning Objectives
At the conclusion of this activity, participants should be better prepared to:
• Appraise testing strategies that may inform clinical decision making in the management of hematologic malignancies
• Apply clinical trial results to multiple lines of care in the management of hematologic malignancies
• Analyze disparities in care for patients with hematologic malignancies
• Outline strategies to monitor and proactively manage treatment-related toxicities in patients with leukemia, lymphoma, and multiple myeloma
• Identify key emerging data pertaining to the diagnosis and management of patients with hematologic malignancies